Skip to content

Auricular Vagal Nerve Stimulation in Peripheral Arterial Disease

Auricular Vagal Nerve Stimulation in Peripheral Arterial Disease - STIVAX Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
DRKS
Registry ID
DRKS00012578
Enrollment
40
Registered
2017-07-27
Start date
2013-09-12
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I70.2

Interventions

Group 1: Intervention Group: Verum Device In this prospective, double blinded trial the stimulation of afferent nerve fibers of the outer ear using an electroacupuncture device was carried out. In

Sponsors

Angiologie, Meduni Graz
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were a written informed consent and a lifestyle-limiting PAOD due to calf-pain in Fontaine-stage IIb existing for at least 6 months. Furthermore, at least one hemodynamically relevant vascular obstruction or vascular occlusion in the arterial femoropopliteal area had to be verified with radiological imaging (MR-Angiography, CT-Angiography, Colour coded Duplex Sonography or Digital Subtraction Angiography).

Exclusion criteria

Exclusion criteria: Relevant exclusion criteria were a known symptomatic diabetic polyneuropathy, claudicatio spinalis, atrial fibrillation, therapy with prostanoids within the last 6 months, structured exercise training within the last 6 months, myocardial infarction within the last 6 months, stroke / transitory ischemic attack within the last 6 months, pregnancy, any kind of paralyses of the limbs, other implanted devices (pacemaker, implanted cardioverter defibrillator, cardiac resynchronization therapy, implanted analgesics pump) as well as a known malignant neoplasia. Moreover, patients were not included in the trial if the walking distance was anamnestically limited by other causes than intermittent claudication (e.g. dyspnoea or chest pain).

Design outcomes

Primary

MeasureTime frame
Significantly more frequent doubling of the maximum (absolute) walking distance (+100%) after 8 cycles (8 weeks) in the verum group compared to controls.

Secondary

MeasureTime frame
Statistically significant improvement of the total score of WIQ as well as statistically significant improvement of Health Related Quality of Life (HRQoL) based on SF-36 after 8 cycles (8 weeks) of therapy.

Countries

Austria

Contacts

Public ContactGerald Hackl

Angiologie, Meduni Graz

gerald.hackl@medunigraz.at004331638580698

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026